4.7 Article

Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection

期刊

JOURNAL OF GASTROENTEROLOGY
卷 57, 期 9, 页码 676-683

出版社

SPRINGER JAPAN KK
DOI: 10.1007/s00535-022-01887-3

关键词

Intrahepatic cholangiocarcinoma; Calcium channel blocker; Resection; Overall survival; Recurrence-free survival

向作者/读者索取更多资源

This study retrospectively evaluated the effects of calcium channel blockers (CCBs) on patients with intrahepatic cholangiocarcinoma. The results showed that the overall survival and recurrence-free survival of patients treated with CCBs were significantly higher, indicating that CCBs treatment might improve the prognosis of patients with intrahepatic cholangiocarcinoma.
Background Intrahepatic cholangiocarcinoma is the second most common primary cancer of the liver. It is highly malignant and its prognosis is very poor. Although there have been various reports on the effects of calcium channel blockers on cancer, the effects of calcium channel blockers on intrahepatic cholangiocarcinoma have not been reported so far. Methods Seventy-nine patients diagnosed with intrahepatic cholangiocarcinoma by hepatectomy between January 2002 and May 2019 were retrospectively evaluated. We compared prognosis and time to recurrence between patients treated with calcium channel blockers (CCBs) (n = 29) and those not treated with CCBs (n = 50). Propensity score matching reduced confounding biases and yielded 25 matched patient pairs. Survival between groups was compared using Kaplan-Meier analyses, logrank tests, and Cox proportional hazard regression models. Results Overall survival and recurrence-free survival of the CCBs group were significantly longer than those of the non-CCBs group OS in the original cohort and matched cohort (98 months vs 45 months, p = 0.010; 96 months vs 22 months, p = 0.020, respectively). Multivariate analyses showed that CCBs treatment was independently associated with overall survival (HR, 0.37; 95% CI 0.16-0.85; p = 0.019) and recurrence-free survival (HR, 0.39; 95% CI 0.17-0.90; p = 0.020) in the original cohort and matched cohort, respectively. Conclusion CCBs treatment might improve prognosis of patients with intrahepatic cholangiocarcinoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据